U.S., Nov. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07228403) titled 'Efficacy and Safety Evaluation of Glepaglutide in Treatment of SBS' on Nov. 13.
Brief Summary: The purpose of this study is to understand the safety and efficacy of twice weekly glepaglutide 10 mg in adult patients with short bowel syndrome (SBS), who were previously enrolled in the EASE SBS 2 or EASE SBS 3 trials. Participants currently on these trials will be able to continue their glepaglutide treatment by enrolling in this EASE SBS 6 extension trial. The trial includes a 24-month treatment period, followed by a 4-week safety follow-up period. Participants will attend trial visits, where they may undergo heart tests (electrocardi...